EUCTR2012-003644-71-ES进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Etanercept in Subjects with Rheumatoid Arthritis Who Have Had and Inadequate Response to Adalimumab or Infliximab Plus Methotrexate.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator´s study team before subjects are included in the study.
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
- •2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Subject is literate and able to complete the protocol-specified questionnaires.
- •Period 1 Inclusion Criteria
- •In addition to the criteria in Section 4.1, subjects must meet all of the following inclusion criteria to be eligible for enrollment into Period 1 of the study:
- •1. Male or female >= 18 years and <80 years of age at the time of consent.
- •2. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 12 weeks after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active (see Section 4.5 Life Style Guidelines)..
- •3. Met the 1987 ACR Revised Criteria for RA (see Appendix 1).
- •4. A history of inadequate efficacy response to at least a 6-month course of either infliximab or adalimumab with at least the last 4 weeks before the screening visit receiving a combination of either infliximab plus MTX or adalimumab plus MTX.
- •5. For subjects receiving infliximab, the last dose of infliximab must have been received within 6 to 8 weeks before the screening mAb ADA test.
- •6. For subjects receiving adalimumab, the last dose of adalimumab must have been received within 11 to 17 day before the screening mAb ADA test.
- •7. Stable dose of oral MTX (10 mg QW to 25 mg QW) for >=6 weeks before the baseline visit.
- •8. Active RA at the screening visit, defined as all of the following:
- •a. CRP >= 1.0 mg/L
- •b. >= 6 tender joints based on the 28 joint assessment (see Section 7.1.5)
- •c. >= 6 swollen joints based on the 28 joint assessment (see Section 7.1.5)
- •9. Active RA at the baseline visit, defined as all of the following:
- •a. >= 6 tender joints based on the 28 joint assessment (see Section 7.1.5)
- •b. >= 6 swollen joints based on the 28 joint assessment (see Section 7.1.5)
- •10.In the opinion of the investigator, subject is a reasonable candidate for treatment with etanercept plus MTX.
- •11.Either the subject or a designee must be capable (according to the investigator?s judgment) of administering the SC investigational product and must be able to store all investigational product under required storage conditions or must be able to come to the study site for administrations where the investigational product may be stored on behalf of the subject.
- •12.Active and latent TB must be ruled out by screening for TB in accordance with local country guidelines; subjects with recent exposure to active TB must be evaluated by a qualified physician to rule out TB (see Period 1 Exclusion Criteria 20).
- •13.Female subjects of childbearing potential per the investigator´s opinion must have negative urine pregnancy test results based on the screening visit and baseline visit tests (see Section 7.4.1 Pregnancy Testing). This includes subjects who are menst
排除标准
- •Period 1 Excl. Criteria
- •1.Investigational site staff members or relatives of those site staff members or Pfizer employees directly involved in trial conduct.
- •2.ACR functional class IV.
- •3.Prior treatment with etanercept, any immunosuppressive biologic agent other than infliximab or adalimumab, or both infliximab and adalimumab.
- •4.Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.
- •5.For subjects receiving infliximab, a dose >10 mg/kg every 4 weeks within 12 weeks before baseline.
- •6.For subjects receiving adalimumab, a dose >40 mg every other week within 12 weeks before baseline.
- •7.Subject has a known or suspected allergy, hypersensitivity, or contraindication to MTX or its components or to etanercept, its excipients, or other compounds related to this class of medication, including biopharmaceutical proteins.
- •8.> 1 permitted non-biologic DMARD other than MTX or change in dose or regimen of the additional permitted non-biologic DMARD within 4 weeks before baseline.
- •9.Cyclophosphamide, cyclosporine, or azathioprine within 6 months before baseline.
- •10.Leflunomide without elimination procedure within 8 weeks before baseline or within 4 weeks of baseline if the protocol-specified elimination procedure is followed.
- •11.Any investigational non-biologic drugs or devices within 12 weeks before baseline and/or during study B1801355.
- •12.Non-biologic DMARDs other than those permitted during the study or which are not listed under other exclusion criteria within 8 weeks before baseline.
- •13.>10 mg/day of oral prednisone (or equivalent),or change in dose within 2 weeks before baseline.
- •14.IA or soft tissue corticosteroid injection or bolus IM or IV corticosteroids within 4 weeks before baseline.
- •15.> 1 NSAID or change in dose or type of NSAID within 2 weeks before baseline.
- •16.Any live (attenuated)vaccines within 4 weeks before baseline.
- •17.Any of the following hematology or chemistry laboratory abnormalities based on screening test results.
- •a.WBC count<=3.5 x 109/L;
- •b.Hemoglobin level <=85 g/L or <=5.3mmol/L;
- •c.Hematocrit <=27%;
- •d.Platelet count <=125 x 109/L;
- •e.Serum creatinine level >=175 µmol/L or >=1.98 mg/dL;
- •f.AST or ALT level ?2 times upper limit of normal.
- •18.Any other clinically significant laboratory results or vital sign measurements.
- •19.Active TB, or evidence of untreated latent or active TB.
- •20.Any infection associated with hospitalization and/or parenteral anti-infective agents within 4 weeks before baseline.
- •21.Active infection at screening and/or baseline, including systemic fungal infections.
- •22.Any clinically relevant concurrent medical conditions, including:
- •a.Uncompensated congestive heart failure, Class III or IV heart failure, or any episode of acute congestive heart failure within 6 months before screening;
- •b.Uncontrolled hypertension;
- •c.Myocardial infarction within 12 months before screening;
- •d.Coronary artery bypass graft or percutaneous transluminal coronary angioplasty within 12 months before screening;
- •e.Unstable angina pectoris within 6 months before screening;
- •f.Presence or history of severe pulmonary disease requiring recurrent hospitalizations or supplemental oxygen;
- •g.Presence or history of confirmed blood dyscrasias;
- •h.Diagnosis of multiple sclerosis or other central or peripheral nervous system demyelinating diseases;
- •i.Malignancy or history of malignancy (except non metastatic basal cell or squamous cell skin carcinoma; or cervical carcinoma in situ);
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82